NJ Drug Co. Dodges Class Action Over FDA Approval Claims

Law360, Newark (May 19, 2017, 9:29 PM EDT) -- A New Jersey federal judge on Friday tossed a proposed securities class action against Eagle Pharmaceuticals Inc., saying investors have failed to back up their claims that the company made false and misleading statements about the nature of a blood thinner and the chances of the drug receiving federal approval.

U.S. District Judge Jose L. Linares granted a dismissal motion from the company and Scott Tarriff, its president and CEO, finding in part that their statements about the likelihood of securing U.S. Food and Drug Administration...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.